TITLE

Structured interruption of treatment hastened disease progression in multidrug-resistant HIV: COMMENTARY

AUTHOR(S)
Walmsley, Sharon
PUB. DATE
May 2004
SOURCE
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p64
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Structured treatment interruption (STI) is being evaluated as a strategy in many stages of HIV infection. A retrospective cohort study suggested that an STI before the initiation of salvage therapy could result in improved viral load and CD4 count responses. A series of controlled trials tested this hypothesis, but the conclusions of these trials conflict. The STI group had better immunologic and virologic responses than the control group with no difference in the incidence of clinical events. Nonetheless, studies suggest that in patients with multidrug-resistant virus, a short STI before the initiation of salvage therapy is unlikely to be beneficial and could be harmful.
ACCESSION #
13221830

 

Related Articles

  • Structured interruption of treatment hastened disease progression in multidrug-resistant HIV.  // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p64 

    This article presents a study, to determine whether structured treatment interruption (STI) more effective than an immediate change in drug regimen for delaying disease progression or death in patients with multidrug-resistant HIV infection. 270 patients who were 13 years of age, had an HIV RNA...

  • Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial. Holodniy, Mark; Brown, Sheldon T.; Cameron, D. William; Kyriakides, Tassos C.; Angus, Brian; Babiker, Abdel; Singer, Joel; Owens, Douglas K.; Anis, Aslam; Goodall, Ruth; Hudson, Fleur; Piaseczny, Mirek; Russo, John; Schechter, Martin; Deyton, Lawrence; Darbyshire, Janet // PLoS ONE;2011, Vol. 6 Issue 3, p1 

    Background: Guidance is needed on best medical management for advanced HIV disease with multidrug resistance (MDR) and limited retreatment options. We assessed two novel antiretroviral (ARV) treatment approaches in this setting. Methods and Findings: We conducted a 2×2 factorial randomized...

  • The VACS Index Accurately Predicts Mortality and Treatment Response among Multi-Drug Resistant HIV Infected Patients Participating in the Options in Management with Antiretrovirals (OPTIMA) Study. Brown, Sheldon T.; Tate, Janet P.; Kyriakides, Tassos C.; Kirkwood, Katherine A.; Holodniy, Mark; Goulet, Joseph L.; Angus, Brian J.; Cameron, D. William; Justice, Amy C. // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Objectives: The VACS Index is highly predictive of all-cause mortality among HIV infected individuals within the first few years of combination antiretroviral therapy (cART). However, its accuracy among highly treatment experienced individuals and its responsiveness to treatment interventions...

  • Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial. Holodniy, Mark; Brown, Sheldon T.; Cameron, D. William; Kyriakides, Tassos C.; Angus, Brian; Babiker, Abdel; Singer, Joel; Owens, Douglas K.; Anis, Aslam; Goodall, Ruth; Hudson, Fleur; Piaseczny, Mirek; Russo, John; Schechter, Martin; Deyton, Lawrence; Darbyshire, Janet // PLoS Clinical Trials;Mar2011, Vol. 8 Issue 3, Special section p1 

    Background: Guidance is needed on best medical management for advanced HIV disease with multidrug resistance (MDR) and limited retreatment options. We assessed two novel antiretroviral (ARV) treatment approaches in this setting. Methods and Findings: We conducted a 262 factorial randomized open...

  • START TRIAL FINDS THAT EARLY TREATMENT IMPROVES OUTCOMES FOR PEOPLE WITH HIV. Cairns, Gus // HIV Australia;Jul2015, Vol. 13 Issue 2, p54 

    The article presents a discussion on the importance of immediate treatment for people with HIV infection, adapted from the website aidsmap.com. Topics discussed include the significance of randomised clinical trial for HIV infected people to prevent AIDS development, the effectiveness of...

  • Progressive symptoms and signs following institution of highly active antiretroviral therapy and subsequent antituberculosis therapy: immune reconstitution syndrome or infection? Miller, R. F.; Shahmanesh, M.; Talbot, M. D.; Wiselka, M. J.; Shaw, P. J.; Bacon, C.; Robertson, C. M. // Sexually Transmitted Infections;Apr2006, Vol. 82 Issue 2, p111 

    A 36 year old man presented with weight loss, cough, fever, and exertional dyspnoea shortly after a diagnosis of HIV infection. Symptoms and initial radiological abnormalities worsened after highly active antiretroviral therapy was started. An eventual diagnosis was established but multiple...

  • Immunogenicity, Immunologic Memory, and Safety Following Measles Revaccination in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy. Abzug, Mark J.; Qin, Min; Levin, Myron J.; Fenton, Terence; Beeler, Judy A.; Bellini, William J.; Audet, Susette; Sowers, Sun Bae; Borkowsky, William; Nachman, Sharon A.; Pelton, Stephen I.; Rosenblatt, Howard M. // Journal of Infectious Diseases;8/15/2012, Vol. 206 Issue 4, p512 

    Background. Response rates and immunologic memory following measles vaccination are reduced in human immunodeficiency virus (HIV)–infected children in the absence of highly active antiretroviral therapy (HAART).Methods. HIV-infected children 2 to <19 years old receiving HAART and with HIV...

  • Emerging Drugs for the Treatment of Human Immunodeficiency Virus. Bhopale, Girish M. // Recent Patents on Anti-Infective Drug Discovery;Apr2012, Vol. 7 Issue 1, p45 

    Rapid emergence of drug resistant Human Immunodeficiency virus (HIV) variants and severe side effects of anti-HIV drugs limit the efficacy of existing anti-HIV therapies. Efforts are being made to develop newer anti-HIV agents. Few newer anti-HIV agents reached the different clinical phases...

  • When More Is Less. Kuritzkes, Daniel R. // Clinical Infectious Diseases;8/15/2004, Vol. 39 Issue 4, p559 

    Landmark studies on the dynamics of HIV-1 infection, conducted nearly a decade ago, provided the theoretical framework on which the modern approach to combination antiretroviral therapy is based. Against this background, AIDS Clinical Trials Group protocol 388 was designed to test the hypothesis...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics